For example, high plasma levels of IL-6 in patients with advanced kidney, breast, and bladder cancer indicate impaired effector differentiation of CD8+ cytotoxic T cells and a poor response to atezolizumab (α-PD-L1) therapy (43). This evidence concerns the gene IL6 and urinary bladder cancer.